TRCT
ALXO icon

Tower Research Capital (TRC)’s ALX Oncology ALXO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5K Buy
+10,397
New +$18.6K ﹤0.01% 3481
2026
Q1 		– Sell
-3,142
Closed -$3.55K – 5099
2025
Q4 		$3.55K Sell
3,142
-696
-18% -$1.05K ﹤0.01% 4351
2025
Q3 		$7.02K Sell
3,838
-6,439
-63% -$5.58K ﹤0.01% 4125
2025
Q2 		$4.27K Sell
10,277
-240
-2% -$121 ﹤0.01% 4352
2025
Q1 		$6.55K Buy
10,517
+5,516
+110% +$6.62K ﹤0.01% 4033
2024
Q4 		$8.35K Sell
5,001
-2,346
-32% -$3.61K ﹤0.01% 3998
2024
Q3 		$13.4K Sell
7,347
-232
-3% -$862 ﹤0.01% 3520
2024
Q2 		$45.7K Buy
7,579
+2,833
+60% +$34.8K ﹤0.01% 3177
2024
Q1 		$52.9K Sell
4,746
-2,815
-37% -$39.5K ﹤0.01% 2238
2023
Q4 		$113K Buy
7,561
+4,120
+120% +$39.1K ﹤0.01% 2561
2023
Q3 		$16.5K Buy
3,441
+1,166
+51% +$6.33K ﹤0.01% 3553
2023
Q2 		$17.1K Sell
2,275
-11,419
-83% -$74.8K ﹤0.01% 3524
2023
Q1 		$62K Buy
13,694
+12,473
+1,022% +$94.5K ﹤0.01% 2306
2022
Q4 		$13K Sell
1,221
-7,979
-87% -$89.6K ﹤0.01% 3570
2022
Q3 		$88K Buy
9,200
+2,110
+30% +$24.6K ﹤0.01% 2667
2022
Q2 		$57K Buy
7,090
+4,226
+148% +$46K ﹤0.01% 2755
2022
Q1 		$48K Sell
2,864
-1,413
-33% -$24.1K ﹤0.01% 2754
2021
Q4 		$92K Buy
4,277
+2,852
+200% +$123K ﹤0.01% 2279
2021
Q3 		$105K Sell
1,425
-205
-13% -$13.7K ﹤0.01% 2354
2021
Q2 		$89K Buy
1,630
+869
+114% +$52K ﹤0.01% 2518
2021
Q1 		$56K Sell
761
-612
-45% -$48.2K ﹤0.01% 3023
2020
Q4 		$118K Sell
1,373
-210
-13% -$12.6K ﹤0.01% 2185
2020
Q3 		$60K Buy
+1,583
New +$62.2K ﹤0.01% 3455

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Tower Research Capital (TRC)'s ALXO Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in ALX Oncology (ALXO) in Q2 2026: 10,397 shares worth $21.5K. The stake represents ﹤0.01% of the portfolio and ranks #3481 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in ALXO as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in ALXO in Q3 2020 and has held it in 23 quarters since. The position peaked at $118K in Q4 2020. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Tower Research Capital (TRC) held 10,397 shares of ALX Oncology worth $21.5K as of Q2 2026.
  • ALX Oncology was a new Tower Research Capital (TRC) position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3481 holding.
  • Tower Research Capital (TRC) first reported a position in ALX Oncology in Q3 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s ALX Oncology position peaked at $118K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.